• Nebivolol Hydrochloride: Advanced Workflows for β1 Blockade

  2026-06-12

  Nebivolol hydrochloride empowers cardiovascular scientists with high selectivity and purity for dissecting β1-adrenergic signaling. This guide translates bench protocols and troubleshooting into actionable steps for reproducible, high-impact assays.

• Rifampin in Mechanistic Transcriptional Modulation Research

  2026-06-12

  Explore the unique role of rifampin as a rifamycin antibiotic in advanced transcriptional regulation studies. This article delves deeper into mechanistic applications, comparative workflows, and practical assay optimization, setting it apart from standard guides.

• Bradykinin B2 Antagonism in Human Synovial Fibroblasts: New

  2026-06-11

  This study characterizes the pharmacology of the non-peptide B2 receptor antagonist MEN16132 versus icatibant in human synovial fibroblasts. The findings elucidate novel pro-inflammatory signaling roles for bradykinin and confirm the potent anti-inflammatory effects of B2 antagonism, with implications for osteoarthritis research and translational inflammation models.

• JNK-IN-7: Selective JNK Inhibitor for Targeted Apoptosis Ass

  2026-06-11

  JNK-IN-7’s unparalleled selectivity empowers researchers to dissect JNK-dependent apoptosis and inflammatory signaling with unprecedented precision. This guide translates recent mechanistic insights into actionable workflows, troubleshooting strategies, and advanced applications, making it essential reading for anyone pursuing MAPK signaling pathway research or innate immune modulation.

• Lanabecestat (AZD3293) in Alzheimer's Disease Research Workf

  2026-06-10

  Lanabecestat (AZD3293) empowers Alzheimer's disease researchers to precisely modulate amyloid-beta production using a potent, blood-brain barrier-permeable BACE1 inhibitor. This guide translates breakthrough findings into practical protocols, troubleshooting strategies, and advanced applications for maximizing the impact of Lanabecestat in neurodegenerative disease models.

• Structural Insights into TRPM3 Modulation by Primidone and N

  2026-06-10

  This study uses cryo-EM to reveal the molecular mechanisms by which neurosteroids and the anticonvulsant Primidone regulate the TRPM3 ion channel. Findings clarify how disease mutations, agonists, and inhibitors alter TRPM3 gating, providing a structural foundation for therapeutic targeting in pain and neurodevelopmental disorders.

• PF-04971729 (Ertugliflozin): Applied Workflows in Diabetes R

  2026-06-09

  Ertugliflozin (PF-04971729) stands out as a benchmark SGLT2 inhibitor in diabetes and renal research, enabling rigorous modeling of glucose reabsorption and cardiometabolic endpoints. This guide details experimental workflows, troubleshooting strategies, and unique translational insights to maximize reproducibility and impact with APExBIO’s reagent.

• Tiamulin Inhibits TNF-α and Alleviates Psoriasis-Like Dermat

  2026-06-09

  A recent high-throughput screening study identified Tiamulin fumarate as a potent small-molecule inhibitor of TNF-α signaling, capable of reducing inflammation in psoriasis-like dermatitis models. This work highlights Tiamulin's translational potential beyond veterinary use, particularly in targeting NF-κB and MAPK pathways implicated in skin inflammation.

• Anagliptin (SK-0403): Advanced Workflows for Vascular Resear

  2026-06-08

  Anagliptin (SK-0403) empowers researchers to dissect DPP-4 inhibition and novel vasorelaxant mechanisms, bridging diabetes and cardiovascular research. This guide delivers actionable workflows, troubleshooting strategies, and highlights translational insights from the latest reference study.

• Applied Research with Ertugliflozin (PF-04971729): Workflows

  2026-06-08

  Ertugliflozin (PF-04971729) offers precision and selectivity for diabetes mellitus research, providing robust modeling of renal glucose reabsorption and cardiovascular endpoints. This guide translates bench-to-impact experimental design, protocol optimization, and troubleshooting for translational and preclinical studies leveraging APExBIO’s gold-standard SGLT2 inhibitor.

• Trelagliptin Succinate Mitigates Cognitive Deficits via PI3K

  2026-06-07

  This study demonstrates that Trelagliptin succinate significantly alleviates cognitive impairment in a rat model of type 2 diabetes by modulating both inflammatory responses and the PI3K/Akt/GSK-3β pathway. The findings provide mechanistic insights into how selective DPP-4 inhibition may protect neural function in diabetes, informing future research on diabetes-related cognitive decline.

• In Vitro Comparison of Aminoglycoside Antibiotics Against Cl

  2026-06-06

  This study provides a robust comparative analysis of the in vitro activity of sisomicin, a newly isolated aminoglycoside antibiotic, against a broad range of clinical gram-negative and gram-positive bacterial isolates. The findings clarify sisomicin's potency relative to established agents like tobramycin, highlighting important considerations for antibiotic resistance research and microbiology assay design.

• Trelagliptin Succinate in Type 2 Diabetes and Bone Research

  2026-06-05

  Trelagliptin succinate (SYR-472 succinate) is redefining diabetes mellitus research by enabling robust, reproducible workflows in both metabolic and bone biology studies. Its long-acting, selective DPP-4 inhibition profile supports advanced experimental design, with proven benefits for osteoblast differentiation and insulin signaling pathways.

• Strategic ROS Assays: DCFH-DA and Translational Redox Biolog

  2026-06-05

  This thought-leadership article explores the mechanistic basis and translational utility of 2,7-Dichlorodihydrofluorescein diacetate (DCFH-DA) in oxidative stress research. Anchored by emerging evidence from PCOS pathophysiology and advanced assay workflows, it offers actionable protocol guidance and strategic insight for researchers aiming to bridge discovery and clinical impact.

• STING Agonist-1: Optimizing B Cell Activation in Immunology

  2026-06-04

  STING agonist-1 empowers researchers to precisely activate the STING pathway, driving robust B cell responses and tertiary lymphoid structure formation. This guide translates cutting-edge findings into actionable protocols, troubleshooting tips, and strategic insights for cancer immunotherapy and inflammation research.

454 records 15/31 page Previous Next First page 上5页 1112131415 下5页 Last page